An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

NCT05363319 · clinicaltrials.gov ↗

RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Cemiplimab
DRUG: Platinum-based chemotherapy

Sponsor

Regeneron Pharmaceuticals